Chinese biotech company BeiGene Ltd announced on Thursday the approval from the China National Medical Products Administration to begin manufacturing commercial supply of its approved anti-PD-1 antibody.
Guangzhou has enhanced investment in advanced manufacturing as a top priority in city's development plan, said Hong Qian, chief of Guangzhou's bureau of commerce.
The 129th session of the China Import and Export Fair, also known as the Canton Fair, will be held online between April 15 and 24, according to the organizer.
In terms of major indicators such as overall shipment size and total cargo value, China-Europe freight trains departing from Guangzhou in the first two months of 2021 have surpassed those departing in the first quarter of 2020 by more than 20 percent.
A series of events including a symposium on cooperation between Guangdong and transnational companies during the 14th Five-Year Plan (2021-25) period and a signing ceremony for strategic cooperation framework agreements were held in Guangzhou on March 2.
Guangzhou ranked second in China, behind only Beijing, in terms of its technical contract turnover in 2020, according to statistics released on Feb 24 by the Ministry of Science and Technology's Torch High Technology Industry Development Center.
BeiGene officially kicked off its fourth plant construction in Huangpu district on Sunday, playing a role to help build the Sino-Singapore Knowledge City in this southern metropolis to become largest production base of anti-cancer drugs in Asia.
Copyright © Foreign Affairs Office of Guangzhou Municipal Government,
Hong Kong and Macao Affairs Office of Guangzhou Municipal Government All rights reserved.
Presented by China Daily.
京ICP备13028878号-28